Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
1-15 of 50562 results
ViraCyte announces positive phase 2 trial results
ViraCyte has announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M.
Contract Research & Services > Clinical Trials > News
Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody
Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.
News
Boehringer initiates phase 1 trials of Zealand’s analogs for obesity and diabetes
By PBR Staff Writer
Zealand Pharma says that its partner Boehringer Ingelheim has launched phase 1 clinical trials to assess glucagon/GLP-1 agonist and an amylin analog as new treatment options for obesity and diabetes.
Contract Research & Services > Clinical Trials > News
Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib
By PBR Staff Writer
Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Ovid Therapeutics recruits first patient in phase 1b/2a trial of TAK-935/OV935 in adults with rare epilepsies
Ovid Therapeutics announced it has randomized the first patient in its Phase 1b/2a clinical trial of TAK-935, also known as OV935, in collaboration with Takeda Pharmaceutical Company Limited.
Contract Research & Services > Clinical Trials > News
EC grants new indication for Soliris to treat refractory generalized myasthenia gravis
Alexion Pharmaceuticals announced that the European Commission (EC) approved the extension of the indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
Regulatory Affairs > News
AstraZeneca, MedImmune, Ethris to develop mRNA therapies for respiratory diseases
By PBR Staff Writer
AstraZeneca and its research and development arm MedImmune have entered into five-year strategic research collaboration with Ethris to develop mRNA therapies for respiratory diseases.
Production & Manufacturing > Manufacturing > News
Ironwood’s Duzallo gets FDA approval for gout-associated hyperuricemia
By PBR Staff Writer
Ironwood Pharmaceuticals’ Duzallo has been approved by the US Food and Drug Administration (FDA) for the treatment of hyperuricemia in patients with uncontrolled gout.
Regulatory Affairs > News
Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody
Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.
Contract Research & Services > Contract Services > News
Samsung Bioepis, Takeda to co-develop multiple novel biologic therapies
Samsung Bioepis has signed collaboration agreement with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.
Drug Research > Drug Discovery & Development > News
AstraZeneca, Merck get FDA approval for expanded use of ovarian cancer drug
By PBR Staff Writer
AstraZeneca and Merck have secured approvals from The US Food and Drug Administration (FDA) to expand the indication for their newly formulated Lynparza to cover a broader group of women suffering from ovarian cancer.
News
Novartis, MMV begin patient trial of antimalarial compound in Africa
By PBR Staff Writer
Novartis and Medicines for Malaria Venture (MMV) have started a patient trial of antimalarial compound, KAF156, in Africa.
Contract Research & Services > Clinical Trials > News
US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS
Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).
Contract Research & Services > Clinical Trials > News
Atreca raises $35m to advance novel cancer immunotherapies
Atreca, a privately held biotechnology company developing novel therapeutics drawn from human immune responses, has closed its Series B round of financing with an investment totaling $35m.
Drug Research > Drug Discovery & Development > News
Pfizer gets FDA nod for blood cancer treatment Besponsa
By PBR Staff Writer
Pfizer has secured approval from the US Food and Drug Administration (FDA) for its Besponsa (inotuzumab ozogamicin) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Regulatory Affairs > News
1-15 of 50562 results